Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN20934 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| REGN20934 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| REGN20934 | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Has a Body Mass Index (BMI) 25 to 35 kg/m\^2 2. Females must be of non-childbearing potential Key Exclusion Criteria: 1. A self-reported change of body weight \>5 kg within approximately 90 days of visit 2 2. History of type 1 or type 2 diabetes 3. History of clinically...
REGN20934 is an investigational small molecule being developed by Regeneron Pharmaceuticals, Inc. for the treatment of overweight or obesity. It is currently in Phase 1 clinical development. The drug is being studied in a clinical trial in the United States.
REGN20934 is being studied for the treatment of overweight or obesity. The ongoing Phase 1 trial is enrolling adults who are overweight or obese. The trial is also open to healthy volunteers, as it is an early-stage study.
REGN20934 is currently in Phase 1 development. There is one active Phase 1 trial that is recruiting participants. No completed trials have been reported for this drug yet.
The Phase 1 trial, NCT07594093, is a randomized, double-blind, placebo-controlled study. It is designed to evaluate the safety and drug concentrations of REGN20934 in adults with overweight or obesity. The trial is recruiting 90 participants in the United States.
The trial is open to adults aged 18 years and older, of all sexes. It includes participants who are overweight or obese, and also accepts healthy volunteers. The study is being conducted in the United States.
REGN20934 is a small molecule, not a biologic. It is being developed as a potential treatment for overweight or obesity. The drug is currently in Phase 1 testing to assess its safety and pharmacokinetics.